BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19507240)

  • 1. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
    Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
    J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
    Lee XA; Verma C; Sim AYL
    Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
    Chen X; Lu W
    Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX.
    Higbee PS; Dayhoff GW; Anbanandam A; Varma S; Daughdrill G
    J Mol Biol; 2024 Jul; 436(13):168626. PubMed ID: 38810774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J; Wang J; Zhang Q; Chen K; Zhu W
    Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
    Huang D; Qi Y; Song J; Zhang JZH
    J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of small molecules affecting p53-MDM2/MDMX interaction by fluorescence polarization.
    Zhang Q; Lu H
    Methods Mol Biol; 2013; 962():95-111. PubMed ID: 23150440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoinhibition of MDMX by intramolecular p53 mimicry.
    Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K; Mane J; Friesen D; Tuszynski J
    J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.